

Miglustat (hydrochloride)

Catalog No: tcsc2777



Available Sizes

Size: 5mg

Size: 10mg

Size: 25mg



Specifications

CAS No:

210110-90-0

Formula:

$C_{10}H_{22}ClNO_4$

Pathway:

Others

Target:

Others

Purity / Grade:

>98%

Solubility:

H₂O : ≥ 34 mg/mL (132.95 mM)

Alternative Names:

N-Butyldeoxynojirimycin, Hydrochloride;NB-DNJ hydrochloride;OGT918 hydrochloride

Observed Molecular Weight:


255.74

Product Description

Miglustat hydrochloride is an inhibitor of glucosylceramide synthase, primarily to treat Type I Gaucher disease (GD1).

Target: Others

Miglustat is an inhibitor of the ceramide-specific glycosyltransferase, which catalyzes the first step of glycosphingolipid biosynthesis and is currently approved for the oral treatment of type 1 GD [1]. Consumption of a standard high-fat breakfast within 30 minutes before administration of miglustat significantly reduced peak exposure but did not significantly affect the extent of systemic exposure to miglustat. The peak plasma concentration (C(max)) decreased by 36% on average following administration with food. Area under the plasma concentration-time curve (AUC(0-infinity)) showed a modest (14%) decrease with food, but the 90% confidence interval was within the acceptance limit of 80% to 125%. The median (min-max) time to C(max) (t(max)) was prolonged from 2.5 (1.0-4.0) hours in the fasted state to 4.5 (1.5-8.0) hours in the fed state, whereas the apparent terminal half-life was approximately 8 hours and not affected by food [2].



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!